Abstract:Regulation of ubiquitination is associated with multiple processes of tumorigenesis and development, including regulation of the tumor immune microenvironment. Deubiquitinating enzymes (DUBs) can remove ubiquitin chains from substrates, thereby stabilizing target proteins and altering and remodeling biological processes. During tumorigenesis, deubiquitination-altered biological processes are closely related to tumor metabolism, stemness, and the immune microenvironment. Recently, tumor microenvironment (TME) modulation strategies have attracted considerable attention in cancer immunotherapy. Targeting immunosuppressive mechanisms in the TME has revolutionized cancer therapy. Prostate cancer (PC) is one of the most common cancers and the second most common cause of cancer-related death in men worldwide. While immune checkpoint inhibition has produced meaningful therapeutic effects in many cancer types, clinical trials of anti-CTLA4 or anti-PD1 have not shown a clear advantage in PC patients. TME affects PC progression and also enables tumor cell immune evasion by activating the PD-1/PD-L1 axis. Over the past few decades, an increasing number of studies have demonstrated that deubiquitination in PC immune microenvironment may modulate the host immune system’s response to the tumor. As the largest and most diverse group of DUBs, ubiquitin-specific proteases (USPs) play an important role in regulating T cell development and function. According to current studies, USPs exhibit a high expression signature in PC and may promote tumorigenesis. Elevated expression of USPs often indicates poor tumor prognosis, suggesting that USPs are expected to develop as the markers of tumor prognosis and even potential drug targets for anti-tumor therapy. Herein, we first summarized recent advances of USPs in PC and focused on the relationship between USPs and immunity. Additionally, we clarified the resistance mechanisms of USPs to targeted drugs in PC. Finally, we reviewed the major achievement of targeting USPs in cancers.

Regulation of T Cell Differentiation and Function by Ubiquitin-Specific Proteases.

Protein Ubiquitination in T Cell Development

Ubiquitin-specific peptidase 22 in cancer

The ubiquitin system in immune regulation.

Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction

USP12 promotes CD4+ T cell responses through deubiquitinating and stabilizing BCL10

USP1-regulated Reciprocal Differentiation of Th17 Cells and Treg Cells by Deubiquitinating and Stabilizing TAZ.

Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch

Regulation of T Cell Function by the Ubiquitin-Specific Protease USP9X Via Modulating the Carma1-Bcl10-Malt1 Complex.

Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion

Immune Regulation by Ubiquitin Tagging As Checkpoint Code.

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

Advance in Research on the Regulation of Innate Immune Response by Ubiquitination

Regulation of the TGF-β Pathway by Deubiquitinases in Cancer.

Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes

Ubiquitin ligases and the immune response.

Ubiquitin specific peptidase 3: an emerging deubiquitinase that regulates physiology and diseases

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

Deubiquitylating Enzymes in Cancer and Immunity

The Regulation of TGF-β/SMAD Signaling by Protein Deubiquitination

Post-Translational Modifications of Deubiquitinating Enzymes: Expanding the Ubiquitin Code